UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 154

Sortiert nach

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

The New England journal of medicine, 2017-01, Vol.376 (2), p.125-135

2017

Volltextzugriff (PDF)

RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner

Cancer research (Chicago, Ill.), 2014-11, Vol.74 (22), p.6661-6670

2014

Volltextzugriff (PDF)

Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors

American journal of nuclear medicine and molecular imaging, 2017-11, Vol.7 (5), p.228-235

2017

Volltextzugriff (PDF)

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Journal of Nuclear Medicine, 2021-09, Vol.62 (9), p.1274-1277

2021

Volltextzugriff (PDF)

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

The Journal of nuclear medicine (1978), 2021-09, Vol.62 (9), p.1274-1277

2021

Volltextzugriff (PDF)

90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1652-1659

2010

Volltextzugriff (PDF)

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

European journal of nuclear medicine and molecular imaging, 2020-09, Vol.47 (10), p.2372-2382

2020

Volltextzugriff (PDF)

90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2018-11, Vol.59 (11), p.1692-1698

2018

Volltextzugriff (PDF)

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

The Journal of nuclear medicine (1978), 2018-11, Vol.59 (11), p.1692-1698

2018

Volltextzugriff (PDF)

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

The Journal of nuclear medicine (1978), 2017-07, Vol.58 (7), p.1054-1057

2017

Volltextzugriff (PDF)

Localization of Unknown Primary Site with 68 Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

Journal of Nuclear Medicine, 2017-07, Vol.58 (7), p.1054-1057

2017

Volltextzugriff (PDF)

Potential for Increasing Uptake of Radiolabeled 68 Ga-DOTATOC and 123 I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat

Cancer biotherapy & radiopharmaceuticals, 2021-10, Vol.36 (8), p.632

2021

Volltextzugriff (PDF)

Does liver tumor burden affect the therapeutic effect of 177Lu-Dotatate treatment? Analysis of Progression Free Survival, Safety and Quality of Life in NETTER-1 study

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Volltextzugriff (PDF)

Safety and efficacy of 68Ga-DOTATOC PET/CT in children and young adults

The Journal of nuclear medicine (1978), 2017-05, Vol.58, p.38

2017

Volltextzugriff (PDF)

Depth Psychology and Mysticism

1, 2018

Volltextzugriff (PDF)

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

The New England journal of medicine, 2017-01, Vol.376 (2), p.125-135

2017

Volltextzugriff (PDF)

Examination of PHOX 2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas

Histopathology, 2017-10, Vol.71 (4), p.503-510

2017

Volltextzugriff (PDF)

Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study

Pancreas, 2018, Vol.47 (3), p.337

2018

Volltextzugriff (PDF)

Abstract 1368: RABL6A, a novel critical regulator of Akt-mTOR signaling in pancreatic neuroendocrine tumor cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1368-1368

2017

Volltextzugriff (PDF)

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience

Pancreas, 2014-05, Vol.43 (4), p.518-525

2014

Volltextzugriff (PDF)

Limitations of Somatostatin Scintigraphy in Primary Small Bowel NETs

The Journal of surgical research, 2014-05, Vol.190 (2), p.548-553

2014

Volltextzugriff (PDF)

The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e14600-e14600

2012

Volltextzugriff (PDF)

The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.308-308

2012

Volltextzugriff (PDF)

Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.332-332

2012

Volltextzugriff (PDF)

Safety and accuracy of 68 Ga-DOTATOC PET/CT in children and young adults with solid tumors

American journal of nuclear medicine and molecular imaging, 2017, Vol.7 (5), p.228

2017

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner

Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

Localization of Unknown Primary Site with 68 Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

Potential for Increasing Uptake of Radiolabeled 68 Ga-DOTATOC and 123 I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat

Does liver tumor burden affect the therapeutic effect of 177Lu-Dotatate treatment? Analysis of Progression Free Survival, Safety and Quality of Life in NETTER-1 study

Safety and efficacy of 68Ga-DOTATOC PET/CT in children and young adults

Depth Psychology and Mysticism

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

Examination of PHOX 2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas

Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study

Abstract 1368: RABL6A, a novel critical regulator of Akt-mTOR signaling in pancreatic neuroendocrine tumor cells

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience

Limitations of Somatostatin Scintigraphy in Primary Small Bowel NETs

The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs)

The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors

Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors

Safety and accuracy of 68 Ga-DOTATOC PET/CT in children and young adults with solid tumors

Aktive Filter

Suchergebnisse filtern